Antiviral Drugs Market Size By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), By Age Group (Pediatric, Adult, Geriatric), Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Mar 2021  |  Report ID: GMI4968  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 200   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry trends

Antiviral Drugs Market size was valued at more than USD 44.1 billion in 2020 and is expected to showcase over -1.7% CAGR from 2021 to 2027. Robust investment in drug research and development by pharmaceutical companies will offer immense growth potential to the market in the coming years. Government and other non-profit organizations have undertaken awareness programmes regarding treatments available for sexually transmitted diseases. With rising adoption of anti-viral drugs, the market is anticipated to witness momentous growth during the forecast timeframe.

Antiviral Drugs Market

Get more details on this report - Request Free Sample PDF
 

Anti-viral drugs are medications that are used during treatment of viral infections including HIV, hepatitis and influenza among other diseases. These drugs include prescription drugs in form of pills, intravenous solution, liquid, and inhaled powders. They are used to treat flu viruses in the body. Anti-viral drugs are classified into different classes such as neuraminidase inhibitors, reverse transcriptase inhibitors (NRTIs and NNRTIs), protease inhibitors and DNA polymerase inhibitors among several others. Number of anti-viral therapeutics have been approved to minimize the global burden of increasing viral diseases.
 

Antiviral Drugs Market Report Coverage
Report Coverage Details
Base Year:2020
Market Size in 2020:USD 44.1 Billion
Forecast Period:2021 to 2027
Forecast Period 2021 to 2027 CAGR:-1.7%
2027 Value Projection:USD 44.8 Billion
Historical Data for:2016 to 2020
No. of Pages:200
Tables, Charts & Figures:175
Segments covered:Drug Class, Indication, Type, Age Group
Growth Drivers:
  • Increasing prevalence of viral infections including COVID-19
  • Presence of pipeline products for HIV treatment
  • Increasing geriatric population
Pitfalls & Challenges:
  • Presence of generics
  • Rising awareness about preventive drugs treatment

Get more details on this report - Request Free Sample PDF
 

Need for minimization of global burden of sexually transmitted diseases will positively influence the market demand

Viral infections are one of the major diseases affecting millions of lives across the globe. Significant efforts have been undertaken in the development of anti-viral medicines over the period by research institutes along with biopharmaceutical and pharmaceutical companies. According to the Joint United Nations Programme on HIV and AIDS, about 24.5 million HIV infected patients were accessing antiretroviral therapy at the end of June 2019. Since the number of patients is increasing, the market will expand at lucrative growth rate over the forecast period.
 

Growing incidence of other infectious diseases such as hepatitis virus, herpes simplex virus and seasonal influenza will contribute to the market revenue during the forecast timeframe. As per the European Centre for Disease Prevention and Control, around 9 million people live with chronic hepatitis infections in the region with several undiagnosed infections. However, decreasing cost of therapy will impact the market expansion in the coming years.
 

Efficiency of nucleoside reverse transcriptase inhibitors in ART therapy will boost the anti-viral drugs supply

Antiviral Drugs Market Size

Get more details on this report - Request Free Sample PDF
 

Reverse transcriptase inhibitors segment in the antiviral drugs market constituted significant revenue share in 2020 led by the availability and affordability with low genetic barriers, these are among the most commonly used drugs in resource-limited regions. As the effective treatment to reduce growing HIV cases across the globe, the anti-viral drugs based on this drug class will register relatively higher demand in the upcoming years.  Additionally, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors are used against HIV and Hepatitis infections. The combination of these drugs refers to highly active antiretroviral therapy for HIV.
 

Increasing number of patients suffering from COVID-19 will offer growth potential to the market

Incidence of infectious viruses such as swine flu, Ebola, Zika virus and coronavirus have created demand for effective anti-viral therapies. Occurrence of COVID-19 pandemic, resulting into casualties and morbidity worldwide will offer immense opportunities for research and development in the industry.
 

Coronavirus infection segment will observe 6.4% growth rate till 2027. Increasing research and development activities pertaining to coronavirus infection will drive the industry revenue. Remdesivir is another clinically proven promising treatment against the infection and tested among few patients. With rising demand for anti-viral drug therapy for coronavirus infection, the segment will grow at significant rate over the forecast period.
 

Rising FDA approval of both generic and branded drugs will positively impact the antiviral drugs market value

Branded drugs segment exceeded USD 31 billion in 2020 due to high cost of branded drugs. Increasing research and development cost coupled with speedy FDA approval further contribute to the market demand. Furthermore, growing incidence of infectious disease coupled with high usage of branded drugs in HIV AIDS treatment will augment the segment growth during the forecast period.
 

Greater mortality rate owing to comorbidities in adults coupled with expanding population pool will foster the demand for anti-viral drugs

Adult segment is estimated to attain a CAGR of -1.6% through 2027. According to the World Health Organization, about 536 million adults were infected with herpes simplex virus (HSV) causing genital herpes. Moreover, as per the Canadian Health Measures Survey, approximately 39% people aged between 35 to 59 years had HSV infection. Thus, growing prevalence of sexually transmitted disease among adult population will influence the demand for anti-viral drugs. 
 

Significant increase in anti-viral drug manufacturing and supply will create the growth opportunity for the North America region

North America antiviral drugs market accounted for 54% of revenue share in 2020 propelled by increasing FDA approval and presence of major players in the region. Also, large population base suffering from several infections will contribute to the industry expansion. Recent incidence of coronavirus outbreak has driven the demand for effective anti-viral drugs, especially in the U.S. region. The country is witnessing significant increase in COVID-19 affected patients and hence will boost demand for anti-viral drugs in the upcoming years.
 

Eminent industry players are focusing on new product launches that will impel the market potential

Some of the companies operating in the market include Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. These industry leaders are adopting various inorganic growth strategies to gain market share and sustainable competitive advantage.
 

Some of the recent industry developments:

  • In May 2020, Merck collaborated with Ridgeback Bio, a bioindication company, to develop oral anti-viral drug against COVID-19. This collaboration enhances firm’s development potential thus strengthening its market position.  
     
  • In April 2020, Vanda Pharmaceuticals announced partnership with University of Illinois at Chicago (UIC) for research and development on novel anti-viral against coronavirus. This will create business growth opportunities for the company.
     
  • In February 2020, Johnson & Johnson extended its partnership with Biomedical Advanced Research Development Authority to develop and screen existing anti-viral medications for coronavirus infection. The strategic partnership will fuel the industry growth.
     

The antiviral drugs market with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:
 

Market, By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

Market, By Indication

  • Influenza
  • HIV AIDS
  • Hepatitis
  • Herpes Simplex Virus (HSV)
  • Coronavirus Infection
  • Others

Market, By Age Group

  • Pediatric
  • Adult
  • Geriatric

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Poland
    • Switzerland
    • Netherlands
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East Asia & Africa
    • South Africa
    • Saudi Arabia
    • UAE
       

Frequently Asked Questions (FAQ) :

Antiviral drugs industry generated nearly USD 44.1 billion in 2020 and will continue to witness increased expenditure in drug research and development by pharmaceutical companies.
Reverse transcriptase inhibitors will record a notable demand through 2027 due to wide utilization in resource limited regions, availability and affordability with low genetic barriers.
Antiviral drugs market share from coronavirus infection segment will expand at a CAGR of 6.4% through 2027 led by ongoing research and development activities.
North America antiviral drugs market captured over 54% revenue share in 2020 and will grow on account of a large patient pool suffering from various infectious diseases including COVID-19.

Premium Report Details

  • Published Date: Mar 2021
  • Pages: 200
  • Tables: 160
  • Charts / Figures: 15
  • Companies covered: 10
  • Countries covered: 28

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X